perindopril has been researched along with Cognition Disorders in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, GF; Han, H; Hu, XD; Qian, YH; Yang, WN | 1 |
| Abo-Youssef, AM; Ali, MR; Khattab, MM; Messiha, BA | 1 |
| Beckett, N; Bulpitt, C; Clarke, R; Fletcher, A; Forette, F; Peters, R; Poulter, R; Ritchie, C; Tuomilehto, J; Waldman, A; Walton, I | 1 |
| Anderson, C; Bousser, MG; Chalmers, J; Coskun, O; Dufouil, C; Godin, O; MacMahon, S; Mazoyer, B; Tzourio, C; Tzourio-Mazoyer, N | 1 |
| Anderson, C; Chalmers, J; Cooper, M; de Galan, BE; Dufouil, C; Grobbee, DE; Hackett, M; Hamet, P; Heller, SR; Lisheng, L; MacMahon, S; Mancia, G; Neal, B; Pan, CY; Patel, A; Pillai, A; Poulter, N; Travert, F; Woodward, M; Zoungas, S | 1 |
| Beardmore, R; Beckett, N; Bulpitt, C; Mitnitski, A; Mt-Isa, S; Peña-Miller, R; Peters, R; Rockwood, K | 1 |
| Jackson, SH; Mukhtar, O | 1 |
| Anderson, C; Chalmers, J; Chapman, N; MacMahon, S; Neal, B; Tzourio, C; Woodward, M | 1 |
| Widimský, J | 1 |
| Cambien, F; Chalmers, J; Chapman, N; Colman, S; Harrap, SB; Leguennec, S; MacMahon, S; Neal, B; Ohkubo, T; Poirier, O; Raoux, S; Tzourio, C; Woodward, M | 1 |
1 review(s) available for perindopril and Cognition Disorders
| Article | Year |
|---|---|
The Hypertension in the Very Elderly Trial - latest data.
Topics: Aged, 80 and over; Antihypertensive Agents; Cognition Disorders; Delayed-Action Preparations; Dementia; Double-Blind Method; Drug Therapy, Combination; Fractures, Bone; Humans; Hypertension; Indapamide; Multicenter Studies as Topic; Perindopril; Randomized Controlled Trials as Topic | 2013 |
4 trial(s) available for perindopril and Cognition Disorders
| Article | Year |
|---|---|
Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis.
Topics: Aged, 80 and over; Antihypertensive Agents; Cardiovascular Diseases; Cognition Disorders; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Indapamide; Longitudinal Studies; Male; Mental Status Schedule; Perindopril; Psychometrics; Risk Factors | 2009 |
Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Brain; Cerebrovascular Disorders; Cognition Disorders; Dementia; Disease Progression; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Perindopril; Predictive Value of Tests; Recurrence; Stroke | 2009 |
Modelling cognitive decline in the Hypertension in the Very Elderly Trial [HYVET] and proposed risk tables for population use.
Topics: Aged, 80 and over; Antihypertensive Agents; Cognition Disorders; Double-Blind Method; Female; Humans; Hypertension; Indapamide; Male; Models, Theoretical; Perindopril | 2010 |
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Cognition; Cognition Disorders; Dementia; Diuretics; Double-Blind Method; Female; Humans; Hypertension; Indapamide; Male; Middle Aged; Perindopril; Risk; Treatment Outcome | 2003 |
5 other study(ies) available for perindopril and Cognition Disorders
| Article | Year |
|---|---|
The effects of perindopril on cognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Animals; Chlorides; Cholinesterase Inhibitors; Cognition Disorders; Galactose; Glutathione Peroxidase; Male; Malondialdehyde; Mice; Oxidative Stress; Perindopril; Superoxide Dismutase | 2013 |
Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Cyclic N-Oxides; Disease Models, Animal; Inflammation Mediators; Lipopolysaccharides; Male; Maze Learning; Mice, Inbred BALB C; Motor Activity; Neuroprotective Agents; Oxidative Stress; Perindopril; Reactive Nitrogen Species; Recognition, Psychology; Spatial Memory; Spin Labels; Time Factors | 2016 |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Educational Status; Female; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Indapamide; Male; Mental Status Schedule; Myocardial Infarction; Perindopril; Risk Factors; Stroke | 2009 |
[Management of dementia and cognitive functions in patients after cerebrovascular stroke: new results from the PROGRESS study].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Cognition Disorders; Dementia; Humans; Hypertension; Indapamide; Middle Aged; Perindopril; Randomized Controlled Trials as Topic; Stroke | 2003 |
The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cognition Disorders; Dementia; Female; Genotype; Humans; Hypertension; Male; Middle Aged; Mutagenesis, Insertional; Peptidyl-Dipeptidase A; Perindopril; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Risk Factors; Sequence Deletion; Statistics as Topic; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Vascular Diseases | 2003 |